Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

Wouter Hendrickx, Ines Simeone, Samreen Anjum, Younes Mokrab, François Bertucci, Pascal Finetti, Giuseppe Curigliano, Barbara Seliger, Luigi Cerulo, Sara Tomei, Lucia Gemma Delogu, Cristina Maccalli, Ena Wang, Lance D. Miller, Francesco M. Marincola, Michele Ceccarelli, Davide Bedognetti

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Cancer immunotherapy is revolutionizing the clinical management of several tumors, but has demonstrated limited activity in breast cancer. The development of more effective treatments is hindered by incomplete knowledge of the genetic determinant of immune responsiveness. To fill this gap, we mined copy number alteration, somatic mutation, and expression data from The Cancer Genome Atlas (TCGA). By using RNA-sequencing data from 1,004 breast cancers, we defined distinct immune phenotypes characterized by progressive expression of transcripts previously associated with immune-mediated rejection. The T helper 1 (Th-1) phenotype (ICR4), which also displays upregulation of immune-regulatory transcripts such as PDL1, PD1, FOXP3, IDO1, and CTLA4, was associated with prolonged patients' survival. We validated these findings in an independent meta-cohort of 1,954 breast cancer gene expression data. Chromosome segment 4q21, which includes genes encoding for the Th-1 chemokines CXCL9-11, was significantly amplified only in the immune favorable phenotype (ICR4). The mutation and neoantigen load progressively decreased from ICR4 to ICR1 but could not fully explain immune phenotypic differences. Mutations of TP53 were enriched in the immune favorable phenotype (ICR4). Conversely, the presence of MAP3K1 and MAP2K4 mutations were tightly associated with an immune-unfavorable phenotype (ICR1). Using both the TCGA and the validation dataset, the degree of MAPK deregulation segregates breast tumors according to their immune disposition. These findings suggest that mutation-driven perturbations of MAPK pathways are linked to the negative regulation of intratumoral immune response in breast cancer. Modulations of MAPK pathways could be experimentally tested to enhance breast cancer immune sensitivity.

Original languageEnglish
Article numbere1253654
JournalOncoImmunology
Volume6
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Genome
Breast Neoplasms
Phenotype
Mutation
Atlases
Neoplasms
Chemokine CXCL9
RNA Sequence Analysis
Neoplasm Genes
Immunotherapy
Up-Regulation
Chromosomes
Gene Expression
Survival
Genes
Therapeutics

Keywords

  • Breast cancer
  • chemokines
  • exome sequencing
  • immune checkpoint
  • immune signatures
  • immunologic constant of rejection
  • MAPK mutations
  • PD-L1
  • predictive signatures
  • prognostic signatures
  • triple negative

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Hendrickx, W., Simeone, I., Anjum, S., Mokrab, Y., Bertucci, F., Finetti, P., ... Bedognetti, D. (2017). Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology, 6(2), [e1253654]. https://doi.org/10.1080/2162402X.2016.1253654

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. / Hendrickx, Wouter; Simeone, Ines; Anjum, Samreen; Mokrab, Younes; Bertucci, François; Finetti, Pascal; Curigliano, Giuseppe; Seliger, Barbara; Cerulo, Luigi; Tomei, Sara; Delogu, Lucia Gemma; Maccalli, Cristina; Wang, Ena; Miller, Lance D.; Marincola, Francesco M.; Ceccarelli, Michele; Bedognetti, Davide.

In: OncoImmunology, Vol. 6, No. 2, e1253654, 01.02.2017.

Research output: Contribution to journalArticle

Hendrickx, W, Simeone, I, Anjum, S, Mokrab, Y, Bertucci, F, Finetti, P, Curigliano, G, Seliger, B, Cerulo, L, Tomei, S, Delogu, LG, Maccalli, C, Wang, E, Miller, LD, Marincola, FM, Ceccarelli, M & Bedognetti, D 2017, 'Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis', OncoImmunology, vol. 6, no. 2, e1253654. https://doi.org/10.1080/2162402X.2016.1253654
Hendrickx, Wouter ; Simeone, Ines ; Anjum, Samreen ; Mokrab, Younes ; Bertucci, François ; Finetti, Pascal ; Curigliano, Giuseppe ; Seliger, Barbara ; Cerulo, Luigi ; Tomei, Sara ; Delogu, Lucia Gemma ; Maccalli, Cristina ; Wang, Ena ; Miller, Lance D. ; Marincola, Francesco M. ; Ceccarelli, Michele ; Bedognetti, Davide. / Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. In: OncoImmunology. 2017 ; Vol. 6, No. 2.
@article{7c777cb0d3be4b68b4e80c8e98302b80,
title = "Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis",
abstract = "Cancer immunotherapy is revolutionizing the clinical management of several tumors, but has demonstrated limited activity in breast cancer. The development of more effective treatments is hindered by incomplete knowledge of the genetic determinant of immune responsiveness. To fill this gap, we mined copy number alteration, somatic mutation, and expression data from The Cancer Genome Atlas (TCGA). By using RNA-sequencing data from 1,004 breast cancers, we defined distinct immune phenotypes characterized by progressive expression of transcripts previously associated with immune-mediated rejection. The T helper 1 (Th-1) phenotype (ICR4), which also displays upregulation of immune-regulatory transcripts such as PDL1, PD1, FOXP3, IDO1, and CTLA4, was associated with prolonged patients' survival. We validated these findings in an independent meta-cohort of 1,954 breast cancer gene expression data. Chromosome segment 4q21, which includes genes encoding for the Th-1 chemokines CXCL9-11, was significantly amplified only in the immune favorable phenotype (ICR4). The mutation and neoantigen load progressively decreased from ICR4 to ICR1 but could not fully explain immune phenotypic differences. Mutations of TP53 were enriched in the immune favorable phenotype (ICR4). Conversely, the presence of MAP3K1 and MAP2K4 mutations were tightly associated with an immune-unfavorable phenotype (ICR1). Using both the TCGA and the validation dataset, the degree of MAPK deregulation segregates breast tumors according to their immune disposition. These findings suggest that mutation-driven perturbations of MAPK pathways are linked to the negative regulation of intratumoral immune response in breast cancer. Modulations of MAPK pathways could be experimentally tested to enhance breast cancer immune sensitivity.",
keywords = "Breast cancer, chemokines, exome sequencing, immune checkpoint, immune signatures, immunologic constant of rejection, MAPK mutations, PD-L1, predictive signatures, prognostic signatures, triple negative",
author = "Wouter Hendrickx and Ines Simeone and Samreen Anjum and Younes Mokrab and Fran{\cc}ois Bertucci and Pascal Finetti and Giuseppe Curigliano and Barbara Seliger and Luigi Cerulo and Sara Tomei and Delogu, {Lucia Gemma} and Cristina Maccalli and Ena Wang and Miller, {Lance D.} and Marincola, {Francesco M.} and Michele Ceccarelli and Davide Bedognetti",
year = "2017",
month = "2",
day = "1",
doi = "10.1080/2162402X.2016.1253654",
language = "English",
volume = "6",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "2",

}

TY - JOUR

T1 - Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

AU - Hendrickx, Wouter

AU - Simeone, Ines

AU - Anjum, Samreen

AU - Mokrab, Younes

AU - Bertucci, François

AU - Finetti, Pascal

AU - Curigliano, Giuseppe

AU - Seliger, Barbara

AU - Cerulo, Luigi

AU - Tomei, Sara

AU - Delogu, Lucia Gemma

AU - Maccalli, Cristina

AU - Wang, Ena

AU - Miller, Lance D.

AU - Marincola, Francesco M.

AU - Ceccarelli, Michele

AU - Bedognetti, Davide

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Cancer immunotherapy is revolutionizing the clinical management of several tumors, but has demonstrated limited activity in breast cancer. The development of more effective treatments is hindered by incomplete knowledge of the genetic determinant of immune responsiveness. To fill this gap, we mined copy number alteration, somatic mutation, and expression data from The Cancer Genome Atlas (TCGA). By using RNA-sequencing data from 1,004 breast cancers, we defined distinct immune phenotypes characterized by progressive expression of transcripts previously associated with immune-mediated rejection. The T helper 1 (Th-1) phenotype (ICR4), which also displays upregulation of immune-regulatory transcripts such as PDL1, PD1, FOXP3, IDO1, and CTLA4, was associated with prolonged patients' survival. We validated these findings in an independent meta-cohort of 1,954 breast cancer gene expression data. Chromosome segment 4q21, which includes genes encoding for the Th-1 chemokines CXCL9-11, was significantly amplified only in the immune favorable phenotype (ICR4). The mutation and neoantigen load progressively decreased from ICR4 to ICR1 but could not fully explain immune phenotypic differences. Mutations of TP53 were enriched in the immune favorable phenotype (ICR4). Conversely, the presence of MAP3K1 and MAP2K4 mutations were tightly associated with an immune-unfavorable phenotype (ICR1). Using both the TCGA and the validation dataset, the degree of MAPK deregulation segregates breast tumors according to their immune disposition. These findings suggest that mutation-driven perturbations of MAPK pathways are linked to the negative regulation of intratumoral immune response in breast cancer. Modulations of MAPK pathways could be experimentally tested to enhance breast cancer immune sensitivity.

AB - Cancer immunotherapy is revolutionizing the clinical management of several tumors, but has demonstrated limited activity in breast cancer. The development of more effective treatments is hindered by incomplete knowledge of the genetic determinant of immune responsiveness. To fill this gap, we mined copy number alteration, somatic mutation, and expression data from The Cancer Genome Atlas (TCGA). By using RNA-sequencing data from 1,004 breast cancers, we defined distinct immune phenotypes characterized by progressive expression of transcripts previously associated with immune-mediated rejection. The T helper 1 (Th-1) phenotype (ICR4), which also displays upregulation of immune-regulatory transcripts such as PDL1, PD1, FOXP3, IDO1, and CTLA4, was associated with prolonged patients' survival. We validated these findings in an independent meta-cohort of 1,954 breast cancer gene expression data. Chromosome segment 4q21, which includes genes encoding for the Th-1 chemokines CXCL9-11, was significantly amplified only in the immune favorable phenotype (ICR4). The mutation and neoantigen load progressively decreased from ICR4 to ICR1 but could not fully explain immune phenotypic differences. Mutations of TP53 were enriched in the immune favorable phenotype (ICR4). Conversely, the presence of MAP3K1 and MAP2K4 mutations were tightly associated with an immune-unfavorable phenotype (ICR1). Using both the TCGA and the validation dataset, the degree of MAPK deregulation segregates breast tumors according to their immune disposition. These findings suggest that mutation-driven perturbations of MAPK pathways are linked to the negative regulation of intratumoral immune response in breast cancer. Modulations of MAPK pathways could be experimentally tested to enhance breast cancer immune sensitivity.

KW - Breast cancer

KW - chemokines

KW - exome sequencing

KW - immune checkpoint

KW - immune signatures

KW - immunologic constant of rejection

KW - MAPK mutations

KW - PD-L1

KW - predictive signatures

KW - prognostic signatures

KW - triple negative

UR - http://www.scopus.com/inward/record.url?scp=85011817556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011817556&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2016.1253654

DO - 10.1080/2162402X.2016.1253654

M3 - Article

AN - SCOPUS:85011817556

VL - 6

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 2

M1 - e1253654

ER -